News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. (ESPR) Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia


10/31/2013 12:18:40 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced dosing of the first patient in a Phase 2b clinical study of ETC-1002, its lead product candidate, in patients with or without statin intolerance and hypercholesterolemia. The goals of this study, ETC-1002-008, are to compare the LDL-C lowering efficacy of ETC-1002 with ezetimibe and to demonstrate comparable tolerability to ezetimibe, a common therapy for statin intolerance, in the treatment of patients with elevated LDL-C levels. To be considered statin intolerant for ETC-1002-008, a patient must be intolerant to two or more statins, at least one of which was administered at or below the approved starting dose. ETC-1002 is an orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES